The Economic Impact of Adrenomyeloneuropathy (AMN) on Direct Medical Costs in Commercially Insured US Adults: A Retrospective Study

Josh Bonkowsky^{1,2}, Bridget Healey³, Naomi C. Sacks³, Ronaé K. McLin³, Philip Cyr³, Eileen Sawyer⁴, Christopher D. Stephen^{5,6}, Florian Eichler^{5,6}

¹Primary Children's Hospital, Intermountain Healthcare, Salt Lake City, UT, ²Division of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, ³Heath Economics and Outcomes Research, PRECISIONheor, Boston, MA, ⁴Clinical Medical Affairs, SwanBio Therapeutics, Boston, MA, ⁵ Department of Neurology, Massachusetts General Hospital, Boston, MA,⁶Harvard Medical School, Boston, MA

INTRODUCTION

- X-linked adrenoleukodystrophy (X-ALD) is a genetic, metabolic condition with an incidence of 1:16,800 caused by a *ABCD1* gene mutation.^{1,2}
- Males with the mutation develop adrenomyeloneuropathy (AMN) in adulthood. Symptom onset is typically observed around the late 20s to 30s. Women may also develop symptoms, though onset is observed later in life.³⁻⁵
- AMN is neurodegenerative characterized by progressive myeloneuropathy that causes spastic paraparesis, sensory ataxia, incontinence, and sexual dysfunction. Eventually walking is severely affected and mobility is impaired.^{3,6-8}
- There are currently no effective treatments in stabilizing or reversing the progression of AMN. Moreover, suggested and practiced care varies based on the symptoms experienced by each person.⁹
- AMN's impact on healthcare resource utilization (HRU) and mortality is unknown.

Objective

• This goal of this study was to quantify for healthcare costs for commercially insured male and female adults with AMN in the US.

Methods

- Direct medical costs were assessed using IQVIA's PharMetrics Plus commercial claims database (1/01/2006-6/30/2021), with nationally representative demographic, enrollment and claims data.
- Study subjects were individuals ages 18-64y with ≥1 inpatient or ≥2 outpatient claims containing an AMN or X-ALD diagnosis (ICD-10-CM: E71.52x; ICD-9-CM 277.86), no evidence of childhood cerebral adrenoleukodystrophy or other peroxisomal disorders and no pregnancy or labor and delivery.
- AMN study patients were 1:4 propensity score matched to non-AMN controls on demographic characteristics and enrollment window.
- Patients and controls were followed for as long as they were observable in the claims data.
- Costs paid to providers by payers were estimated per patient per month (PPPM) and annualized to represent costs per patient per year (PPPY)

man L, Moser AB, Raymond GV, et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol. Apr 2001;49(4):512-7 2. Resende LL, de Paiva ARB, Kok F, da Costa Leite C, Lucato LT. Adult Leukodystrophies: A Step-by-Step Diagnostic Approach Radiographics. Jan-Feb 2019;39(1):153-168. doi:10.1148/rg.2019180081 3. Engelen M, Kemp S, de Visser M, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. Aug 13 2012;7:51. doi:10.1186/1750-1172-7-51 4. Kanakis G, Kaltsas G Adrenoleukodystrophy. [Updated 2018 Oct 12]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. 5. Zhu, J., Eichler, F., Biffi, A., Duncan, C. N., Williams, D. A., & Majzoub, J. A. (2020). The Changing Face of Adrenoleukodystrophy. Endocr Rev, 41(4), 577-593. https://doi.org/10.1210/endrev/bnaa013 6. Zhang YZ, G.: Chen, W.: Pu, Z.: Song, L.: Tang, X.: Liu, Z. A novel ABCD1 G1202A mutation in a Chinese patient with pure adrenomyeloneuropathy and literature review. Genes Dis. Sep 2021;8(5):709-714. doi:10.1016/j.gendis.2020.01.009 7. Dato C, Capaldo G, Terracciano C, et al. Late adult-onset adrenomyeloneuropathy evolving with atypical severe frontal lobe syndrome: Importance of neuroimaging. Radiol Case Rep. Mar 2019;14(3):309-314. doi:10.1016/j.radcr.2018.11.007 8. Kemp S, Berger J, Aubourg P. X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta. Sep 2012;1822(9):1465-74. doi:10.1016/j.bbadis.2012.03.012 9. Eichler F, Duncan C, Musolino PL, et al. Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med. 2017;377(17):1630-1638.

Results

- A total of 806 individuals with evidence of AMN (Males:303; Females: 503) were matched to 2,726 (Males: 1,037; Females: 1,689) similar in age, sex, geography, and length of enrollment.
- Most individuals with AMN were between ages 18-35y, mean age 35.1y \pm 13.81 (males) and 35.0 \pm 11.56 (females).
- Mean follow-up in males was 29.0 \pm 27.69 months and female 18.9 \pm 19.74 months.
- Mean Charlson Comorbidity Index (CCI) scores were 0.67 \pm 0.94 (males) and 0.34 \pm 1.33 (females).

Figure 1: Annual All-cause Healthcare Costs AMN vs. Controls, By Sex





© 2023 SwanBio Therapeutics, Inc. All rights reserved

- \$2,028±21,491, considerably higher than controls (\$369±3,931), p < 0.05
 - 19%) constituting the remainder.
- than costs for male and female controls.
 - vs. male controls, p < 0.05 (Figure 1A).
 - AMN vs. female controls, p < 0.05 (Figure 1B).

 - largest differences in male patients compared with controls (Figure 2).



CONCLUSIONS

- AMN are much higher than adults without AMN, particularly for male patients.
- assessment for patients with AMN.

Author contributions: FE, JB, BH, NS, RM, PC, ES, and CS contributed to the design and implementation of the study, and to the interpretation of results Disclosures: JB has received consultant fees from Bluebird bio, Neurogene, Passage Bio, Takeda, and Autobahn; owns stock in Orchard; received research support from NIH. RM, BH, NS, and PC received employee salary from PrecisionHEOR. ES received employee salary from and owns stock in uniQure Inc; received research support from Sanofi and NIH. CS has received consultant fees from SwanBio; received research support from Sanofi. FE has received consultant fees from SwanBio, Alnylam, Origin Biosciences, Orchard, Autobahn, Bluebird; received fees from UpToDate; received research support from Bluebird, Minoryx, and Sio; owns stock in SwanBio.





• Across all AMN patients, mean all-cause healthcare monthly per patient costs paid by payers were

• Inpatient admissions accounted for nearly half of all monthly per patient costs (\$950±21,017, 47%), with outpatient services (\$684±2,876; 34%) and prescription medications (\$394±\$1,850;

• Annualized costs for both males (n=303) and females (n=503) with AMN were substantially greater

• All-cause annual average total costs were \$26,247 higher per patient among males with AMN

• All-cause annual average total costs were \$14,205 higher per patient among the females with

 Costs for inpatient admissions, outpatient services, and pharmacy fills were significantly higher for male and female AMN patients vs. controls, *p* < 0.05 (Figures 1A and 1B).

• Annual hospitalization rates were much higher for individuals with AMN vs. controls, with the

Figure 2: Annual average hospitalizations PPPY: AMN vs. Controls

• All-cause direct medical costs for commercially insured adult men and women aged 18-64 years old with

Higher costs for AMN patients suggest greater disease-related healthcare issues for patients than has been previously recognized and constitute a substantial overall financial and healthcare burden.

These costs do not include indirect, societal, or patient paid costs and thus do not represent a full cost

The increased costs for both men and women with AMN suggest a need for improved care options.